Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in 2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild cognitive impairment (MCI), and 211 with Alzheimer's disease dementia (AD)) as an 'Inception cohort' who underwent detailed ssessments every 18 months. Over the past decade, an additional 1247 subjects have been added as an 'Enrichment cohort' (as of 10 April 2019). Objective Here we provide an overview of these Inception and Enrichment cohorts of more than 8,500 person-years of investigation. Methods Participants underwent reassessment every 18 months including comprehensive cognitive testing, neuroimaging (magnetic resonance imaging, MRI; positron emission tomography, PET), biofluid biomarkers and lifestyle evaluations. Results AIBL has made major contributions to the understanding of the natural history of AD, with cognitive and biological definitions of its three major stages: preclinical, prodromal and clinical. Early deployment of Aβ-amyloid and tau molecular PET imaging and the development of more sensitive and specific blood tests have facilitated the assessment of genetic and environmental factors which affect age at onset and rates of progression. Conclusion This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. Harmonization with similar large longitudinal cohort studies is underway to further these aims.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 1,112 participants. The Australian AIBL study has followed 2,359 people since 2006: 1,112 in the original cohort (cognitively normal, mild cognitive impairment and Alzheimer's dementia) plus 1,247 added later. Each person is retested every 18 months with cognitive tests, MRI and amyloid/tau PET scans, blood biomarkers and lifestyle measures, for more than 8,500 person-years in total.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fowler, C., Rainey-Smith, SR., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., et al. (2021). Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's disease reports. https://doi.org/10.3233/adr-210005

Vancouver

Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, et al. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's disease reports. 2021. doi:10.3233/adr-210005. PMID: 34368630.

BibTeX

@article{fowler2021-34368630,
  author  = {Fowler, C. and Rainey-Smith, SR. and Bird, S. and Bomke, J. and Bourgeat, P. and Brown, B. M. and Burnham, S. C. and Bush, A. I. and others},
  title   = {{Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease}},
  journal = {Journal of Alzheimer's disease reports},
  year    = {2021},
  doi     = {10.3233/adr-210005},
  pmid    = {34368630},
  url     = {https://doi.org/10.3233/adr-210005}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

The Australian AIBL study has followed 2,359 people since 2006: 1,112 in the original cohort (cognitively normal, mild cognitive impairment and Alzheimer's dementia) plus 1,247 added later. Each person is retested every 18 months with cognitive tests, MRI and amyloid/tau PET scans, blood biomarkers and lifestyle measures, for more than 8,500 person-years in total. The authors say this has helped define the preclinical, prodromal and clinical stages of Alzheimer's and has made it possible to study factors linked to age at onset and speed of progression. It is a description of a research resource, not a test of any treatment.

Study details

How this study scored 66/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 63 of the 96 points it could be judged on, which is 66 of 100. Total 66 of 100.63 of the 96 points we could judge = 66 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 63 of the 96 points we could judge it on, which is 66 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease reports)
Journal's citation record 0 / 4 Journal of Alzheimer s Disease Reports: journal h-index 40 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 3 / 4 1,112 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 167 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 23.9 citations a year over 7 year(s) since 2021
Impact for its field and year 4 / 6 Cited 15.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 3 / 4 Cited 111 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 1 / 3 University of Pittsburgh: institution h-index 1,470 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 18 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34368630)
Free to read 2 / 2 Free to read
Points 63 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 63 of the 96 points we could judge it on is 66 out of 100.
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →